首页> 外文期刊>Bone marrow transplantation >Reduced- intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry- based study
【24h】

Reduced- intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry- based study

机译:减少强度调理同种异体造血细胞移植急性髓性白血病患者:基于注册表的研究

获取原文
获取原文并翻译 | 示例
       

摘要

Clinical efficacy of allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) for younger patients remains unclear. We therefore performed a retrospective registry-based study to evaluate outcomes for patients with AML aged between 16 and 49 years who underwent RIC allogeneic HCT. Patients receiving RIC (N = 125) showed significantly worse survival than those receiving myeloablative conditioning (MAC; N = 1,554) (47.7% for RIC and 54.2% for MAC at 4 years, P = 0.047). However, the difference became marginal after adjustment for patient characteristics (P = 0.080), and inclusion in the multivariate analysis of the HCT comorbidity index or the propensity score for estimating the likelihood of choosing RIC or MAC further reduced statistical significance (P = 0.371 and 0.206, respectively), indicating the existence of a selection bias against RIC. Nevertheless, outcomes for our patients receiving RIC were still acceptable, so that RIC constitutes a potential therapeutic option for younger AML patients who are deemed unsuitable for MAC. Subgroup analyses showed that patients aged between 40 and 49 years as well as those in first or second CR at the time of transplantation exhibited similar outcomes regardless of whether they were treated with RIC or MAC.
机译:同种异体造血细胞移植(HCT)使用减少强度调节(RIC)对年轻患者的临床疗效仍不清楚。因此,我们进行了一种以备注的注册管理机构的研究,以评估患有16至49岁的AML患者的结果,患有RIC同种异体HCT。接受RIC(n = 125)的患者显示出的存活率比接受霉菌调理(MAC; N = 1,554)(RIC 47.7%,4岁以下的54.2%,P = 0.047)。然而,差异在调整患者特性后变得边缘(P = 0.080),并夹杂在HCT合并症指数的多变量分析或倾向评分,以估计选择RIC或MAC的可能性进一步降低统计学意义(P = 0.371和0.206分别为0.206,表明对RIC的选择偏差。尽管如此,接受RIC的患者的结果仍然可以接受,因此RIC构成对被认为不适合Mac的患者的潜在治疗选择。亚组分析表明,在移植时40至49岁的患者以及在移植时的第一或第二CR中的患者表现出类似的结果,无论它们是否被Ric或Mac治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号